FDA Places Clinical Hold on Venetoclax Trials for Multiple Myeloma
This action does not impact currently approved indications for venetoclax.
This action does not impact currently approved indications for venetoclax.
Novo Nordisk announced that the Food and Drug Administration (FDA) has approved Esperoct (turoctocog alfa pegol, N8-GP) for the treatment of patients with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes and perioperative management of bleeding.